Eric L. Wallace

Dr. Eric L. Wallace

Nephrology | Internal Medicine
2000 6th Ave S, 
Birmingham, AL 
Offers Telehealth
2000 6th Ave S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Eric Wallace is an Internal Medicine provider in Birmingham, AL. Dr. Wallace is rated as an Experienced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Fabry Disease, Chronic Kidney Disease, Megalencephalic Leukoencephalopathy with Subcortical Cysts, Multiple Sulfatase Deficiency, and Thrombectomy.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Alabama School Of Medicine
Residency
University of Alabama Hospital
Specialties
Nephrology
Internal Medicine
Licenses
Internal Medicine in FL
Board Certifications
Nephrology
Hospital Affiliations
University Of Alabama At Birmingham Hospital
Languages Spoken
English
Spanish
Gender
Male
Awards
Distinguished Service Award, UAB Medical Alumni Association - 2018
Dean’s Excellence Award for Service - 2017
Outstanding Teacher, Division of Nephrology - 2016
Nominee:The Brewer-Heslin Award for Professionalism in Medicine - 2016
Recognized as one of Birmingham’s Best Physician’s, B-Metro Magazine - 2015

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Nephrology Clinic at The Kirklin Clinic of UAB Hospital
2000 6th Ave S, Birmingham, AL 35233

Additional Areas of Focus

Dr. Wallace has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Alport Syndrome
Fabry Disease
Primary Hyperoxaluria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Biological
Study Drug: 4D-310
Study Phase: Phase 1/Phase 2
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis
Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis
Enrollment Status: Completed
Publish Date: October 01, 2021
Intervention Type: Other
View 3 Less Clinical Trials

64 Total Publications

Rationale and design of the FREEDOM trial: A hybrid type 1 optimization-implementation trial to improve type 2 diabetes management in primary care.
Rationale and design of the FREEDOM trial: A hybrid type 1 optimization-implementation trial to improve type 2 diabetes management in primary care.
Journal: Contemporary clinical trials
Published: March 05, 2025
Similar Doctors
Experienced in Sepsis
Dr. Waleed W. Siddiqi
Nephrology | Geriatrics
Experienced in Sepsis
Dr. Waleed W. Siddiqi
Nephrology | Geriatrics

Tuscaloosa Nephrology Associates PC

1850 Mcfarland Blvd N, 
Tuscaloosa, AL 
 (47.3 miles away)
205-556-5541
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Waleed Siddiqi is a Nephrologist and a Geriatrics provider in Tuscaloosa, Alabama. Dr. Siddiqi is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Nephrosclerosis, Renovascular Hypertension, Acute Kidney Failure, and End-Stage Renal Disease (ESRD). Dr. Siddiqi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wallace's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile